Pathnova Laboratories (PATHNOVA) Enters into Partn
Post# of 1418
(Total Views: 1038)
Posted On: 08/03/2020 7:57:45 AM
Pathnova Laboratories (PATHNOVA) Enters into Partnership to Commercialize Todos Medicals COVID-19 and Breast Cancer Tests in Singapore
AUGUST 03, 2020 7:00AM EDT
Temasek Life Sciences Accelerator-backed PATHNOVA to Offer COVID-19 Testing Kits Supplied by Todos in Singapore and Southeast Asia
REHOVOT, Israel, SINGAPORE and NEW YORK, NY, Aug. 03, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer’s disease, today announced a partnership with PATHNOVA, a Singapore-based clinical laboratory, for the Company’s breast cancer and SARS-CoV-2 diagnostic kits (the “Todos Tests”). PATHNOVA is a spin-off company of Temasek Life Sciences Laboratory (TLL), a not-for-profit research institute with a mission to harness the power of the life sciences to improve lives.
“We are very pleased to work with Todos and its advanced AI-driven TM-B1 and TM-B2 blood tests for breast cancer,” said Professor Chan Soh Ha, CEO of PATHNOVA and previous Executive Director of TLL. “We see immediate potential to offer COVID-19 testing services and to distribute Todos’ COVID-19 tests in Southeast Asia. We believe the Todos portfolio has tremendous potential and we are excited to help bring it forward in Singapore and Southeast Asia.”
Under the terms of the agreements, PATHNOVA will be responsible for the further development and commercialization of the Todos Tests in Singapore, and Todos will assist PATHNOVA in commercializing its nasopharyngeal cancer tests through its affiliates in the United States and Singapore. Todos will provide PATHNOVA with access to existing clinical datasets for its breast cancer diagnostics TM-B1 and TM-B2, and PATHNOVA will work closely with Todos to optimize its AI-driven algorithm to support regulatory approval in the United States and Singapore. Reciprocally, Todos will distribute PATHNOVA’s nasopharyngeal cancer clinical test services through its affiliates in Israel and the United States. PATHNOVA will provide support as a commercial distributor of clinical test services for Todos’ COVID-19 test offerings in Singapore and in Southeast Asia, in collaboration with Todos’ wholly-owned subsidiary Todos Medical Singapore PTE Ltd.
Commenting on the agreement, Gerald Commissiong, Todos Medical’s President & CEO, said, “We have been systematically building a world-class diagnostics company, and this agreement with PATHNOVA supports our goals and extends our geographic reach. By serving as our laboratory in Southeast Asia, along with its ability to shepherd regulatory clearances, PATHNOVA will play an important role in Todos Medical’s growth, while together we provide potentially life-saving diagnostic tests.”
For information related to Todos Medical’s COVID-19 testing capabilities, please visit www.todoscovid19.com
https://investor.todosmedical.com/news-events...nership-to
AUGUST 03, 2020 7:00AM EDT
Temasek Life Sciences Accelerator-backed PATHNOVA to Offer COVID-19 Testing Kits Supplied by Todos in Singapore and Southeast Asia
REHOVOT, Israel, SINGAPORE and NEW YORK, NY, Aug. 03, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer’s disease, today announced a partnership with PATHNOVA, a Singapore-based clinical laboratory, for the Company’s breast cancer and SARS-CoV-2 diagnostic kits (the “Todos Tests”). PATHNOVA is a spin-off company of Temasek Life Sciences Laboratory (TLL), a not-for-profit research institute with a mission to harness the power of the life sciences to improve lives.
“We are very pleased to work with Todos and its advanced AI-driven TM-B1 and TM-B2 blood tests for breast cancer,” said Professor Chan Soh Ha, CEO of PATHNOVA and previous Executive Director of TLL. “We see immediate potential to offer COVID-19 testing services and to distribute Todos’ COVID-19 tests in Southeast Asia. We believe the Todos portfolio has tremendous potential and we are excited to help bring it forward in Singapore and Southeast Asia.”
Under the terms of the agreements, PATHNOVA will be responsible for the further development and commercialization of the Todos Tests in Singapore, and Todos will assist PATHNOVA in commercializing its nasopharyngeal cancer tests through its affiliates in the United States and Singapore. Todos will provide PATHNOVA with access to existing clinical datasets for its breast cancer diagnostics TM-B1 and TM-B2, and PATHNOVA will work closely with Todos to optimize its AI-driven algorithm to support regulatory approval in the United States and Singapore. Reciprocally, Todos will distribute PATHNOVA’s nasopharyngeal cancer clinical test services through its affiliates in Israel and the United States. PATHNOVA will provide support as a commercial distributor of clinical test services for Todos’ COVID-19 test offerings in Singapore and in Southeast Asia, in collaboration with Todos’ wholly-owned subsidiary Todos Medical Singapore PTE Ltd.
Commenting on the agreement, Gerald Commissiong, Todos Medical’s President & CEO, said, “We have been systematically building a world-class diagnostics company, and this agreement with PATHNOVA supports our goals and extends our geographic reach. By serving as our laboratory in Southeast Asia, along with its ability to shepherd regulatory clearances, PATHNOVA will play an important role in Todos Medical’s growth, while together we provide potentially life-saving diagnostic tests.”
For information related to Todos Medical’s COVID-19 testing capabilities, please visit www.todoscovid19.com
https://investor.todosmedical.com/news-events...nership-to
(0)
(0)